CoChat

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression

Open access

The DOI matches its Crossref record; 205 of the 210 references it cites were found in a registry or an index.

Abstract

Approximately 90% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC). PDAC is the fourth leading cause of cancer death world-wide. Therapies for PDAC are largely ineffective due to the dense desmoplastic tumor microenvironment which prevents chemotherapeutic drugs and small molecule inhibitors from exerting effective anti-cancer effects. In this review, we will discuss the roles of TP53 and miRs on the PDAC tumor microenvironment and how loss of the normal functions of TP53 promote tumor progression. The TP53 gene is mutated in approximately 50% of pancreatic cancers. Often, these TP53 mutations are point mutations which confer additional functions for the TP53 proteins. These are called gain of function (GOF) mutations (mut). Another class of TP53 mutations are deletions which result in loss of the TP53 protein; these are referred to TP53-null mutations. We have organized this review into various components/properties of the PDAC microenvironment and how they may be altered in the presence of mutant TP53 and loss of certain miR expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells11142155

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Sites of Interactions of Mutant Genes in PDAC and the Various Pathways which they Effect and also Sites of Interaction of Certain Small Molecule Inhibitors Discussed in this Review. Abbreviations: transforming growth factor-β (TGF-β), small mothers against decapentaplegic homolog 4 protein (SMAD4), small mothers against decapentaplegic homolog 3 protein (SMAD3), small mothers against decapentaplegic homolog 2 protein (SMAD2), Kruppel-like factor 4 (KLF4), Kruppel-like factor 2 (KLF2), cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase inhibitor 2A encoded by CDKN2A (p16 INK4a) E2F transcription factor (E2F), cyclin-dependent kinase inhibitor 1A encoded by CDKN1A (p21Cip1), small molecule reactivator of mutant TP53 (APR-246), TP53 = tumor suppressor protein 53 KDa, 14 KDa tumor suppressor protein alternate reading frame protein encoded by CDKN2A (p14ARF), p53 upregulated modulator of apoptosis (PUMA), mouse double minute 2 E3 ubiquitin ligase (MDM2), small molecular inhibitor of MDM2 (nutlin-3a), micro RNA (miR), non-coding RNAs including LncRNAs and circRNAs (ncRNA), platelet-derived growth factor receptor (PDGFR), cancer-associated fibroblast (CAF), tumor necrosis factor-α (TNFα), tumor necrosis factor receptor (TNFR), sonic hedgehog growth factor (Shh), Ral guanine nucleotide exchange factor (RalGEF), TANK binding kinase 1 (TBK1), inhibitor of NF-Kappa-B kinase-α/β/γ (IKKα/β/κ), inhibitor of NF-κB-α (IκB-α), p50 KDa subunit of nuclear kappa-κB cells (p50), p65 KDa subunit of nuclear kappa-κB cells (p65), small molecule multi kinase inhibitor (Sorafenib), platelet-derived growth factor (PDGF), phosphatase and tensin homolog (PTEN), insulin-like growth factor-I (IGF-1), insulin-like growth factor-1 receptor-1 (IGF-1R), Kirsten Ras oncogene homolog (KRas), phosphatidylinositol 3-kinase (PI3K) 3-phosphoinositide-dependent protein kinase-1 (PDK1), AKT serine/threonine kinase (AKT), (TSC1 (hamartin) and TSC2 (tuberin) tumor suppressor complex (TSC1/TSC2), Ras Homolog, mTORC1 binding protein (Rheb), mechanistic target of rapamycin kinase (mTORC1), SWItch/Sucrose Non-Fermentable complex (SWI/SNF), AT-rich interactive domain-containing protein 1A (Arid1a)—MAP kinase kinase kinase (Raf), mitogen-activated protein kinase kinase 1 (MEK), ERK = mitogen-activated protein kinase (ERK). We compiled the information necessary for all the figures, designed all the figures and their composition was created with BioRender.com.
Figure 1 Sites of Interactions of Mutant Genes in PDAC and the Various Pathways which they Effect and also Sites of Interaction of Certain Small Molecule Inhibitors Discussed in this Review. Abbreviations: transforming growth factor-β (TGF-β), small mothers against decapentaplegic homolog 4 protein (SMAD4), small mothers against decapentaplegic homolog 3 protein (SMAD3), small mothers against decapentaplegic homolog 2 protein (SMAD2), Kruppel-like factor 4 (KLF4), Kruppel-like factor 2 (KLF2), cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase inhibitor 2A encoded by CDKN2A (p16 INK4a) E2F transcription factor (E2F), cyclin-dependent kinase inhibitor 1A encoded by CDKN1A (p21Cip1), small molecule reactivator of mutant TP53 (APR-246), TP53 = tumor suppressor protein 53 KDa, 14 KDa tumor suppressor protein alternate reading frame protein encoded by CDKN2A (p14ARF), p53 upregulated modulator of apoptosis (PUMA), mouse double minute 2 E3 ubiquitin ligase (MDM2), small molecular inhibitor of MDM2 (nutlin-3a), micro RNA (miR), non-coding RNAs including LncRNAs and circRNAs (ncRNA), platelet-derived growth factor receptor (PDGFR), cancer-associated fibroblast (CAF), tumor necrosis factor-α (TNFα), tumor necrosis factor receptor (TNFR), sonic hedgehog growth factor (Shh), Ral guanine nucleotide exchange factor (RalGEF), TANK binding kinase 1 (TBK1), inhibitor of NF-Kappa-B kinase-α/β/γ (IKKα/β/κ), inhibitor of NF-κB-α (IκB-α), p50 KDa subunit of nuclear kappa-κB cells (p50), p65 KDa subunit of nuclear kappa-κB cells (p65), small molecule multi kinase inhibitor (Sorafenib), platelet-derived growth factor (PDGF), phosphatase and tensin homolog (PTEN), insulin-like growth factor-I (IGF-1), insulin-like growth factor-1 receptor-1 (IGF-1R), Kirsten Ras oncogene homolog (KRas), phosphatidylinositol 3-kinase (PI3K) 3-phosphoinositide-dependent protein kinase-1 (PDK1), AKT serine/threonine kinase (AKT), (TSC1 (hamartin) and TSC2 (tuberin) tumor suppressor complex (TSC1/TSC2), Ras Homolog, mTORC1 binding protein (Rheb), mechanistic target of rapamycin kinase (mTORC1), SWItch/Sucrose Non-Fermentable complex (SWI/SNF), AT-rich interactive domain-containing protein 1A (Arid1a)—MAP kinase kinase kinase (Raf), mitogen-activated protein kinase kinase 1 (MEK), ERK = mitogen-activated protein kinase (ERK). We compiled the information necessary for all the figures, designed all the figures and their composition was created with BioRender.com.CC BY · PubMed Central
Figure 2 Potential Sites of where Certain Immunotherapeutic Drugs and Inhibitors may Act in the PDAC Microenvironment. Panels (A,B) immunotherapeutic approaches to target PDAC cells with: (A) αPD-1 MoAb and (B) αCTLA-4 MoAb. Panels (C,D) effects of hypoxia on M2 macrophage polarization and the PDAC microenvironment in Panel (C), where HIF-2 signaling is intact and Panel (D), where HIF-2 signaling is suppressed after treatment with HIF inhibitors PT2399 or Belzutifan. CD8+ cells = CD8 positive T cells (CD8+ cells), PDAC tumor cells (PDAC cells), monoclonal antibody to programmed cell death protein 1 (αPD-1 MoAb), monoclonal antibody to cytotoxic T lymphocyte antigen-4 (αCTLA-4 MoAb), hypoxia inducible factor-2α (HIF-2α), hypoxia-inducible factor-2β (HIF-2β) small molecule HIF-2α inhibitor (PT2399, PT2977), small molecule HIF-2α inhibitor (Belzutifan, MK-6482).
Figure 2 Potential Sites of where Certain Immunotherapeutic Drugs and Inhibitors may Act in the PDAC Microenvironment. Panels (A,B) immunotherapeutic approaches to target PDAC cells with: (A) αPD-1 MoAb and (B) αCTLA-4 MoAb. Panels (C,D) effects of hypoxia on M2 macrophage polarization and the PDAC microenvironment in Panel (C), where HIF-2 signaling is intact and Panel (D), where HIF-2 signaling is suppressed after treatment with HIF inhibitors PT2399 or Belzutifan. CD8+ cells = CD8 positive T cells (CD8+ cells), PDAC tumor cells (PDAC cells), monoclonal antibody to programmed cell death protein 1 (αPD-1 MoAb), monoclonal antibody to cytotoxic T lymphocyte antigen-4 (αCTLA-4 MoAb), hypoxia inducible factor-2α (HIF-2α), hypoxia-inducible factor-2β (HIF-2β) small molecule HIF-2α inhibitor (PT2399, PT2977), small molecule HIF-2α inhibitor (Belzutifan, MK-6482).CC BY · PubMed Central
Figure 3 Various miRs, LncRNA and circRNAs Induced by TP53 which have Effects on: Proliferation, EMT, Migration, Invasion, Metastasis, Desmoplasia and Drug Resistance. Programed cell death ligand 1 (PD-L1), B-cell lymphoma-2 gene (Bcl2), AXL = AXL receptor tyrosine kinase, plasminogen activator inhibitor-1 (serpine-1), signal transducer and activator of transcription 3 (STAT3), matrix metallopeptidase 3 (MMP3), matrix metallopeptidase 9 (MMP9), programmed cell death 4 (PDCD4), chemokine ligand 7 (CCL7), MyD88 = myeloid differentiation primary response protein MyD88 (MyD88), IL-6 = interleukin 6 (IL-6), Zinc finger E-box-binding homeobox 1/Zinc finger E-box-binding homeobox 2 (ZEB1/2).
Figure 3 Various miRs, LncRNA and circRNAs Induced by TP53 which have Effects on: Proliferation, EMT, Migration, Invasion, Metastasis, Desmoplasia and Drug Resistance. Programed cell death ligand 1 (PD-L1), B-cell lymphoma-2 gene (Bcl2), AXL = AXL receptor tyrosine kinase, plasminogen activator inhibitor-1 (serpine-1), signal transducer and activator of transcription 3 (STAT3), matrix metallopeptidase 3 (MMP3), matrix metallopeptidase 9 (MMP9), programmed cell death 4 (PDCD4), chemokine ligand 7 (CCL7), MyD88 = myeloid differentiation primary response protein MyD88 (MyD88), IL-6 = interleukin 6 (IL-6), Zinc finger E-box-binding homeobox 1/Zinc finger E-box-binding homeobox 2 (ZEB1/2).CC BY · PubMed Central
Figure 4 Effects of miRs induced by TP53 which have Effects on Glucose Transport, Aerobic Glycolysis, TCA Cycle, Survival in the Hypoxic PDAC Microenvironment and Metastasis. v-Myc avian myelocytomatosis viral oncogene homolog (c-Myc), mucin 13 (MUC13), PFK1 = phosphofructokinase-1 (PFK1), tricarboxylic acid cycle (TCA).
Figure 4 Effects of miRs induced by TP53 which have Effects on Glucose Transport, Aerobic Glycolysis, TCA Cycle, Survival in the Hypoxic PDAC Microenvironment and Metastasis. v-Myc avian myelocytomatosis viral oncogene homolog (c-Myc), mucin 13 (MUC13), PFK1 = phosphofructokinase-1 (PFK1), tricarboxylic acid cycle (TCA).CC BY · PubMed Central
Figure 5 Effects of GOF mut-TP53 on PDGF-Rβ Expression in PDAC Tumor Cells Growth, Fibrosis and Metastasis. CD8+ cytotoxic T lymphocyte (CD8+ CTL), TP53 family member p73 (p73), nuclear factor-Y transcription factor (NF-Y).
Figure 5 Effects of GOF mut-TP53 on PDGF-Rβ Expression in PDAC Tumor Cells Growth, Fibrosis and Metastasis. CD8+ cytotoxic T lymphocyte (CD8+ CTL), TP53 family member p73 (p73), nuclear factor-Y transcription factor (NF-Y).CC BY · PubMed Central
Figure 6 Effects of TP53 Signaling Pathways and Cellular Stress and NUPR1 and NUPR1L Expression. Cyclic AMP response element binding protein1 (CREB1), interleukin 8 (IL8), interleukin 18 (IL18), helix-loop-helix nuclear protein 1 (NUPR1), NUPR1 ligand (NUPR1L), inhibitor of NF-κB kinase-2 (IKK2), inhibitor of NF-κB (IκB), p50 NF-κB/RelA one NF-κB related proteins, v-Rel avian reticuloendotheliosis viral oncogene homolog B (p50/RelA), ATF4 = activating transcription factor 4 (ATF4), lipocalin 2 (LNC2), small molecule inhibitor of NUPR1 (ZZW-115).
Figure 6 Effects of TP53 Signaling Pathways and Cellular Stress and NUPR1 and NUPR1L Expression. Cyclic AMP response element binding protein1 (CREB1), interleukin 8 (IL8), interleukin 18 (IL18), helix-loop-helix nuclear protein 1 (NUPR1), NUPR1 ligand (NUPR1L), inhibitor of NF-κB kinase-2 (IKK2), inhibitor of NF-κB (IκB), p50 NF-κB/RelA one NF-κB related proteins, v-Rel avian reticuloendotheliosis viral oncogene homolog B (p50/RelA), ATF4 = activating transcription factor 4 (ATF4), lipocalin 2 (LNC2), small molecule inhibitor of NUPR1 (ZZW-115).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Cited by

See all 54

Metadata

Authors
McCubrey, J. A., Yang, L. V., Abrams, S. L., Steelman, L. S., Follo, M. Y., Cocco, L., Ratti, S., Martelli, A. M., Augello, G., & Cervello, M.
Affiliations
  • East Carolina University (US)
  • University of Bologna (IT)
  • Institute for Biomedical Research and Innovation (IT)
Corresponding author
McCubrey, James A.
Venue
Cells
Publisher
MDPI AG
Published
2022-07-09
Volume
11
Issue
14
Pages
2155
ISSN
2073-4409 (ISSN-L)
OpenAlex
W4285014119
Cited by
49
References
210
Citations by year
2026: 5 · 2025: 20 · 2024: 17 · 2023: 3 · 2022: 4
FWCI
1.34
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • East Carolina University Grant (#111104, #111110-668715-0000)
  • Fondazione del Monte di Bologna e Ravenna Research grant (#111104, #111110-668715-0000)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
TP53 mutation, microRNA, pancreatic ductal adenocarcinoma, tumor microenvironment, desmoplasia, immune response, tumor progression, gain-of-function mutations, chemoresistance
MeSH terms
Humans, Immunity, Mutation, Pancreatic Neoplasms, Tumor Suppressor Protein p53, Carcinoma, Pancreatic Ductal, MicroRNAs, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.